Analgesic synergy of neurotensin receptor subtype 2 agonist NT79 and morphine

Behavioural Pharmacology

Volumn 22, Issue 5-6, 2011, Pages 573-581

  Boules, Mona ^a   Johnston, Hannah ^a   Tozy, Jessica ^a   Smith, Kristin ^a   Li, Zhimin ^a   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

formalin test; neurotensin; neurotensin receptors; pain; rats; synergy; writhing test

Indexed keywords

FORMALDEHYDE; MORPHINE; NEUROTENSIN; NEUROTENSIN 79; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 2; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BITE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENTIATION; HOT PLATE TEST; NONHUMAN; PAIN; RAT; SPINAL CORD; VISCERAL PAIN; WRITHING TEST;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; MORPHINE; NEUROTENSIN; PAIN; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTENSIN;

EID: 80051938467     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283474a3a     Document Type: Article

References (47)

1. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A (1999). Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156:1646-1649. (Pubitemid 29460002)
2. Bolan EA, Tallarida RJ, Pasternak GW (2002). Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther 303:557-562. (Pubitemid 35231226)
3. Boules M, Fredrickson P, Richelson E (2003). Current topics: brain penetrating neurotensin analog. Life Sci 73:2785-2792. (Pubitemid 37158020)
4. Boules M, Fredrickson P, Richelson E (2005). Neurotensin agonists as an alternative to antipsychotics. Expert Opin Investig Drugs 14:359-369. (Pubitemid 40711847)
5. Boules M, Shaw A, Liang Y, Barbut D, Richelson E (2009). NT69L, a novel analgesic, shows synergy with morphine. Brain Res 1294:22-28.
6. Boules M, Liang Y, Briody S, Miura T, Fauq I, Oliveros A, et al. (2010). NT79: a novel neurotensin analog with selective behavioral effects. Brain Res 1308:35-46.
7. Bredeloux P, Costentin J, Dubuc I (2006). Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice. Behav Brain Res 175:399-407. (Pubitemid 44750246)
8. Buhler AV, Choi J, Proudfit HK, Gebhart GF (2005). Neurotensin activation of the NTR1 on spinally-projecting serotonergic neurons in the rostral ventromedial medulla is antinociceptive. Pain 114:285-294. (Pubitemid 40279111)
9. Carraway R, Leeman SE (1973). The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248:6854-6861.
10. Chalon P, Vita N, Kaghad M, Guillemot M, Bonnin J, Delpech B, et al. (1996). Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett 386:91-94. (Pubitemid 26173063)
11. Clineschmidt BV, McGuffin JC, Bunting PB (1979). Neurotensin: antinocispon-sive action in rodents. Eur J Pharmacol 54:129-139.
12. Coderre TJ, Fundytus ME, McKenna JE, Dalal S, Melzack R (1993). The formalin test: a validation of the weighted-scores method of behavioural pain rating. Pain 54:43-50. (Pubitemid 23200570)
13. Coquerel ADI, Kitabgi P, Costentin J (1988). Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin N. Neurochem Int 12:361-366.
14. Dubuc I, Sarret P, Labbe-Jullie C, Botto JM, Honore E, Bourdel E, et al. (1999). Identification of the receptor subtype involved in the analgesic effect of neurotensin. J Neurosci 19:503-510. (Pubitemid 29028989)
15. Fantegrossi WE, Ko MC, Woods JH, Richelson E (2005). Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys. Pharmacol Biochem Behav 80:341-349. (Pubitemid 40173966)
16. Fauq AH, Hong F, Cusack B, Tyler BM, Pang YP, Richelson E (1998). Synthesis of (2S)-2-amino-3-(1H-4-indolyl) propanoic acid, a novel trryptophan analog for structural modification of bioactive peptides. Tetrahedron: Asymmetry 9:4127-4134. (Pubitemid 29009758)
17. Gessner PK (1995). Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105:161-179. (Pubitemid 26038237)
18. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroen-docrine responses. Arch Gen Psychiatry 51:199-214.
19. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19.
20. Lutfy K, Shen KZ, Woodward RM, Weber E (1996). Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test. Brain Res 731:171-181. (Pubitemid 26294920)
21. Luttinger D, Burgess SK, Nemeroff CB, Prange AJ (1983). The effects of chronic morphine treatment on neurotensin-induced antinociception. Psychopharma-cology (Berl) 81:10-13. (Pubitemid 13038253)
22. Maeno H, Yamada K, Santo-Yamada Y, Aoki K, Sun YJ, Sato E, et al. (2004). Comparison of mice deficient in the high-or low-affinity neurotensin receptors, Ntsr1 or Ntsr2, reveals a novel function for Ntsr2 in thermal nociception. Brain Res 998:122-129. (Pubitemid 38077132)
23. Mazella J (2001). Sortilin/neurotensin receptor-3: a new tool to investigate neurotensin signaling and cellular trafficking? Cell Signal 13:1-6. (Pubitemid 32222966)
24. Mazella J, Botto JM, Guillemare E, Coppola T, Sarret P, Vincent JP (1996). Structure, functional expression, and cerebral localization of the levocabas-tine-sensitive neurotensin/neuromedin N receptor from mouse brain. J Neurosci 16:5613-5620. (Pubitemid 26293385)
25. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV (2004). Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29:208-218. (Pubitemid 38068031)
26. Nishiyama T (2000). Interaction between intrathecal morphine and glutamate receptor antagonists in formalin test. Eur J Pharmacol 395:203-210. (Pubitemid 30254369)
27. Osbahr AJ, Nemeroff CB, Luttinger D, Mason GA, Prange AJ (1981). Neurotensin-induced antinociception in mice: antagonism by thyrotropin-releasing hormone. J Pharmacol Exp Ther 217:645-651. (Pubitemid 11082249)
28. Pettibone DJ, Hess JF, Hey PJ, Jacobson MA, Leviten M, Lis EV, et al. (2002). The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J Pharmacol Exp Ther 300:305-313. (Pubitemid 34028541)
29. Porro CA, Cavazzuti M, Lui F, Giuliani D, Pellegrini M, Baraldi P (2003). Independent time courses of supraspinal nociceptive activity and spinally mediated behavior during tonic pain. Pain 104:291-301. (Pubitemid 36840901)
30. Remaury A, Vita N, Gendreau S, Jung M, Arnone M, Poncelet M, et al. (2002). Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia. Brain Res 953:63-72. (Pubitemid 35217808)
31. Roussy G, Dansereau MA, Dore-Savard L, Belleville K, Beaudet N, Richelson E, Sarret P (2008). Spinal NTS1 receptors regulate nociceptive signaling in a rat formalin tonic pain model. J Neurochem 105:1100-1114. (Pubitemid 351590777)
32. Roussy G, Dansereau MA, Baudisson S, Ezzoubaa F, Belleville K, Beaudet N, et al. (2009). Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity. Mol Pain 5:38-52.
33. Sarret P, Esdaile MJ, Perron A, Martinez J, Stroh T, Beaudet A (2005). Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors. J Neurosci 25:8188-8196. (Pubitemid 41292113)
34. Sevostianova N, Zvartau E, Bespalov A, Danysz W (2003). Effects of morphine on formalin-induced nociception in rats. Eur J Pharmacol 462:109-113. (Pubitemid 36183741)
35. Shannon HE, Eberle EL, Peters SC (2005). Comparison of the effects of anticonvulsant drugs with diverse mechanisms of action in the formalin test in rats. Neuropharmacology 48:1012-1020. (Pubitemid 40602609)
36. Smith DJ, Hawranko AA, Monroe PJ, Gully D, Urban MO, Craig CR, et al. (1997). Dose-dependent pain-facilitatory and-inhibitory actions of neurotensin are revealed by SR 48692, a nonpeptide neurotensin antagonist: influence on the antinociceptive effect of morphine. J Pharmacol Exp Ther 282:899-908. (Pubitemid 27340194)
37. Stiller CO, Gustafsson H, Fried K, Brodin E (1997). Opioid-induced release of neurotensin in the periaqueductal gray matter of freely moving rats. Brain Res 774:149-158. (Pubitemid 28007894)
38. Sugimoto M, Kuraishi Y, Satoh M, Takagi H (1986). Involvement of medullary opioid-peptidergic and spinal noradrenergic systems in the regulation of formalin-induced persistent pain. Neuropharmacology 25:481-485. (Pubitemid 16036362)
39. Tanaka K, Masu M, Nakanishi S (1990). Structure and functional expression of the cloned rat neurotensin receptor. Neuron 4:847-854. (Pubitemid 20208510)
40. Tershner SA, Helmstetter FJ (2000). Antinociception produced by mu opioid receptor activation in the amygdala is partly dependent on activation of mu opioid and neurotensin receptors in the ventral periaqueductal gray. Brain Res 865:17-26. (Pubitemid 30256203)
41. Tyler BM, Cusack B, Douglas CL, Souder T, Richelson E (1998a). Evidence for additional neurotensin receptor subtypes: neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception. Brain Res 792:246-252. (Pubitemid 28267537)
42. Tyler BM, McCormick DJ, Hoshall CV, Douglas CL, Jansen K, Lacy BW, et al. (1998b). Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo. FEBS Lett 421:280-284. (Pubitemid 28045771)
43. Tyler BM, Douglas CL, Fauq A, Pang YP, Stewart JA, Cusack B, et al. (1999). In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier. Neuropharmacology 38:1027-1034. (Pubitemid 29240619)
44. Tyler-McMahon BM, Stewart JA, Farinas F, McCormick DJ, Richelson E (2000). Highly potent neurotensin analog that causes hypothermia and antinocicep-tion. Eur J Pharmacol 390:107-111. (Pubitemid 30122443)
45. Vincent JP, Mazella J, Kitabgi P (1999). Neurotensin and neurotensin receptors. Trends Pharmacol Sci 20:302-309. (Pubitemid 29301684)
46. Vissers KC, Geenen F, Biermans R, Meert TF (2006). Pharmacological correlation between the formalin test and the neuropathic pain behavior in different species with chronic constriction injury. Pharmacol Biochem Behav 84: 479-486. (Pubitemid 44292247)
47. Vita N, Chalon P, Donat F, Bachy A, Kaghad M, Guillemot M, et al. (1997). Molecular cloning and characterization of a new human neurotensin binding site that recognizes levocabastine. Soc Neurosci 23:394.